Clinical Trial Update: Cohort Event Monitoring Study of Pyramax® [Phase 4]

View source ↗

Summary

Phase 4 cohort event monitoring study of Pyramax for malaria caused by Plasmodium falciparum has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Pyramax (pyronaridine-artesunate)

Snippet

Sponsor: Shin Poong Pharmaceutical Co. Ltd. | Conditions: Malaria,Falciparum | Phase 4 | Status: COMPLETED